Comparison of 68Ga-DOTATOC biodistribution in patients with and without spleenectomy.

Ga-68 labeled somatostatin analogues such as 68Ga-DOTA0-Phe1-Tyr3-octrotide (DOTATOC) as PET tracers, have significantly improved the imaging of somatostatin receptors (SSTRs) expressing tumors. Due to unspecific parenchymal binding and the expression of SSTRs on leukocytes in the spleen this is the organ with the highest non-tumor uptake of DOTATOC. Therefore, we investigated the potential changes of normal tissue distribution and tumor concentration in patients with neuroendocrine tumors (NETs) with or without spleenectomy.
Out of 420 patients with pancreatic NET undergoing 68GA-DOTATOC PET/CT eleven patients with and eleven patients without spleenectomy were derived and matched in regard to tumor histology, tumor load, age and gender. The SUV(max) of liver metastases as well as of the following normal tissues was determined: pituitary gland, thyroid gland, liver parenchyma, kidneys and suprarenal glands.
SUV(max) values with and without spleenectomy were: in the liver metastasis (19.17 ± 6.05 versus 37.67 ± 16.31), in the thyroid gland (2.56 ± 1.33 versus 2.66 ± 0.94), in the pituitary gland (4.08 ± 1.79 versus 4.92 ± 1.93) in suprarenal glands (7.18 ± 3.33 versus 9.73 ± 3.46 on the left side and 7.32 ± 3.03 versus 11.19 ± 5.72 on the right side), in the kidneys (8.1 3 ± 4.26 on the left side and 8.11 ± 4.16 on the right side versus 8.62 ± 2.17 on the left side and 9.79 ± 2.18 on the right side) and in normal liver tissue (5.74 ± 1.55 versus 6.22 ± 1.95). The difference was statistically significant (Wilcoxon test P<0.05) in tumor lesions, adrenal and kidney tissue.
Spleenectomy must be considered as a relevant factor when reporting the outcome of SSTR targeted diagnostics and therapies.
AuthorsC Kratochwil, E Mavriopoulou, D Rath, A Afshar-Oromieh, D Apostolopoulos, S Haufe, W Mier, U Haberkorn, F L Giesel
JournalThe quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology (Q J Nucl Med Mol Imaging) Vol. 59 Issue 1 Pg. 116-20 (Mar 2015) ISSN: 1824-4785 [Print] Italy
PMID24382404 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Organometallic Compounds
  • Radiopharmaceuticals
  • Receptors, Somatostatin
  • Octreotide
  • Adult
  • Aged
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neuroendocrine Tumors (metabolism, radionuclide imaging)
  • Octreotide (analogs & derivatives, pharmacokinetics)
  • Organ Specificity
  • Organometallic Compounds (pharmacokinetics)
  • Pancreatic Neoplasms (metabolism, radionuclide imaging)
  • Positron-Emission Tomography (methods)
  • Radiopharmaceuticals (pharmacokinetics)
  • Receptors, Somatostatin (metabolism)
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Splenectomy
  • Tissue Distribution
  • Whole Body Imaging (methods)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: